Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Advances Day 2019 | Allo-transplant for myelofibrosis

Donal McLornan • 15 Nov 2019
MPN Advances Day 2019
Myelofibrosis Myeloproliferative Neoplasms

Donal McLornan, MB BCh, MRCP, PhD, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the retrospective study by the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party on myeloablative and reduced-intensity conditioning allo-transplant for myelofibrosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Donal McLornan

Novel approaches to upfront management of myelofibrosis 14:17
Novel approaches to upfront management of myelofibrosis
Donal McLornan et al. • 27 Jun 2025
EBMT CMWP data at ASH: MPN-U and second transplant 1:29
EBMT CMWP data at ASH: MPN-U and second transplant
Donal McLornan • 15 Nov 2019

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs 2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals